Merck Sharp & Dohme Corp. has described 3-oxopiperazine carboxamide derivatives acting as sodium channel protein type 10 subunit alpha (Nav1.8) blockers reported to be useful for the treatment of cough, pruritus, acute and neuropathic pain.

Katholieke Universiteit Leuven has patented compounds reported to useful for the treatment of epilepsy.

Scientists at USA Elixiria Biotech Inc. and colleagues described data from preclinical studies evaluating the potential of the peroxisome proliferator-activated receptor γ (PPARγ) agonist, ELB-00824, for protection against chemotherapy-induced neuropathic pain (CINP).

Brain insulin signaling is known to control peripheral energy metabolism and regulation of mood and cognition. Dysregulation in this signaling has been tied to brain pathological disorders such as Alzheimer’s disease (AD). Previous findings have reported a strong connection between type 2 diabetes (T2D) and AD, suggesting insulin resistance as a potential risk factor for AD pathology and other forms of dementia.